Malignant Hypertension: Current Perspectives and Challenges.
Boulestreau R, van den Born BH, Lip GYH, Gupta A.
J Am Heart Assoc. 2022 Apr 5;11(7):e023397. doi: 10.1161/JAHA.121.023397. Epub 2022 Mar 15.
Pharmacological management of malignant hypertension.
Lewek J, Bielecka-Dąbrowa A, Maciejewski M, Banach M.
Expert Opin Pharmacother. 2020 Jul;21(10):1189-1192. doi: 10.1080/14656566.2020.1732923. Epub 2020 Feb 26.
Malignant Hypertension Revisited-Does This Still Exist?
Shantsila A, Lip GYH.
Am J Hypertens. 2017 Jun 1;30(6):543-549. doi: 10.1093/ajh/hpx008.
Malignant Hypertension and Bilateral Primary Aldosteronism.
Murai S, Kakeshita K, Imamura T, Koike T, Fujioka H, Yamazaki H, Kinugawa K.
Intern Med. 2023 Sep 15;62(18):2675-2680. doi: 10.2169/internalmedicine.1098-22. Epub 2023 Feb 1.
Malignant hypertension: not quite an obsolete diagnosis yet.
Shantsila A, Lip GYH.
J Hypertens. 2019 Feb;37(2):282-283. doi: 10.1097/HJH.0000000000001974.
Malignant hypertension and hypertensive emergencies.
Kitiyakara C, Guzman NJ.
J Am Soc Nephrol. 1998 Jan;9(1):133-42. doi: 10.1681/ASN.V91133.
Malignant hypertension and multiorgan damage: mechanisms to be elucidated and countermeasures.
Saito T, Hasebe N.
Hypertens Res. 2021 Jan;44(1):122-123. doi: 10.1038/s41440-020-00555-4. Epub 2020 Oct 7.
Malignant hypertension.
Kincaid-Smith P.
J Hypertens. 1991 Oct;9(10):893-9.
[Malignant hypertension].
Seki A.
Nihon Rinsho. 2000 Jan;58 Suppl 1:795-9.
[Malignant hypertension].
Arita M, Nishio I.
Ryoikibetsu Shokogun Shirizu. 1996;(12):17-21.
